RE:RE:Tocagen misses in Ph3 Glioma trialsIf there is any proof needed that it will all come down to the Clinic it is Tocagen.
Yes Longholder a disruptive technology coupled with thorough preclinical and now Clinical proof of concept have put TLT in a great place.
For me (DYOR) it is only a matter of time now.